Important Notice: Euthyrox^® U.S. Discontinuation

Following Provell Pharmaceuticals' discontinuation of commercialization regarding Euthyrox^® earlier in 2025, EMD Serono has made the difficult decision not to continue commercialization of Euthyrox® (Levothyroxine tablet) in the United States.

It is important to note that this discontinuation of product in the US is not related to the quality, safety, or efficacy of Euthyrox^®. This decision was based on business considerations

Current Supply Status: Please note that the New Drug Application for Euthyrox^® was withdrawn in November 2025 and it will become increasingly difficult to access remaining stock available in the US with expiration date of September 2026. We recommend proactive patient outreach and transition planning.

Support Available: We remain committed to supporting healthcare professionals and patients through this transition.

Contact Information:

Medical Information Team: 1-888-275-7376 (Mon-Fri, 8:00 AM- 5:30 PM ET)

Email: emediusa@emdserono.com

Website: medical.emdserono.com

Investigational agents and investigational indications for marketed products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee that any product will be approved in the sought-after indication.